Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 2 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 5 patents granted in the last 365 days
Orionis Biosciences BV currently has 3 pending office actions in the Biotechnology & Pharmaceuticals technology area. These 3 actions are assigned to 3 distinct examiners across 2 distinct art units. Chang Yu Wang is the busiest examiner with 1 pending action.
With 3 distinct examiners each handling 1 action, the prosecution is currently decentralized at the individual level. The presence of 2 distinct art units suggests that the biotechnology matters are split between two different technical focuses. For the practitioner, this means navigating the specific requirements of 2 art units while addressing the unique feedback from 3 different examiners.
Since Chang Yu Wang and the other examiners each have 1 pending action, there is no primary examiner to focus on. The strategy must be flexible enough to handle 3 separate reviews. By analyzing the 2 art units, the legal team can identify broader trends in biotechnology prosecution that may affect these 3 actions, even as they deal with 3 different examiners.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (33%) |
| Double-patenting + other | 2 (67%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| WANG, CHANG YU | 1 | 33.5% | +53.5% |
| HOPKINS, SAMANTHA LAKE | 1 | 60.4% | +62.3% |
| DUFFY, BRADLEY | 1 | 54.5% | +45.8% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18668770 | CLEC9A BINDING AGENTS AND USE THEREOF | WANG, CHANG YU | — |
| 17598570 | CHIMERIC PROTEINS AND CHIMERIC PROTEIN COMPLEXES DIRECTED TO FMS-LIKE TYROSINE KINASE 3 (FLT3) | HOPKINS, SAMANTHA LAKE | — |
| 17042512 | BI-FUNCTIONAL PROTEINS AND CONSTRUCTION THEREOF | DUFFY, BRADLEY | — |
| Art Unit | Apps |
|---|---|
| 1641 | 1 |
| 1643 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18668770 | CLEC9A BINDING AGENTS AND USE THEREOF | WANG, CHANG YU | — | §112DP | Non-Final OA | — | Pending | May 20, 2024 |
| 17598570 | CHIMERIC PROTEINS AND CHIMERIC PROTEIN COMPLEXES DIRECTED TO FMS-LIKE TYROSINE KINASE 3 (FLT3) | HOPKINS, SAMANTHA LAKE | 1641 | §112DP | Non-Final OA | — | Pending | Sep 27, 2021 |
| 17042512 | BI-FUNCTIONAL PROTEINS AND CONSTRUCTION THEREOF | DUFFY, BRADLEY | 1643 | §103 | Final Rejection | — | Pending | Sep 28, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial